Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CN Coherence NeuroCompany profile Investigational implants and bioelectronic systems for monitoring and treating cancer. Investigational implants and bioelectronic systems for monitoring and treating cancer. | £346.4K | Innovate UK Smart grantUndisclosed | Biotech, Healthtech | United States | Investors Undisclosed | |
| PB Pangea Bio develops medicines for central nervous system disorders. | $100K | One Mind Accelerator investmentUndisclosed | Biotech | United Kingdom | Investors | |
| H Holobiome develops therapies and products based on the human microbiome. | $100K | One Mind Accelerator investmentUndisclosed | Biotech | United States | Investors | |
| DH Dionysus HealthcareCompany profile Dionysus Healthcare develops molecular diagnostics for maternal mental health. Dionysus Healthcare develops molecular diagnostics for maternal mental health. | $100K | One Mind Accelerator investmentUndisclosed | Biotech | United States | Investors | |
| NT Neobe TherapeuticsCompany profile Neobe Therapeutics develops engineered bacterial medicines intended to help cancer drugs and immune cells reach solid tumours. Neobe Therapeutics develops engineered bacterial medicines intended to help cancer drugs and immune cells reach solid tumours. | $2.3M | Early-stage financingUndisclosed | Biotech | United Kingdom | Investors | |
| DT Delix TherapeuticsCompany profile Delix Therapeutics develops neuroplastogen medicines for psychiatric and neurological disorders. Delix Therapeutics develops neuroplastogen medicines for psychiatric and neurological disorders. | $320K | NIDA research grantUndisclosed | Biotech | United States | Investors | |
| RB Revascular Bio Co., Ltd.Company profile Revascular Bio develops cell therapies using vascular endothelial stem cells. Revascular Bio develops cell therapies using vascular endothelial stem cells. | ¥220M | OUVC2 investmentUndisclosed | Biotech | Japan | Investors | |
| m mbiomicsCompany profile mbiomics develops live bacterial therapeutics using precisely designed microbial communities. mbiomics develops live bacterial therapeutics using precisely designed microbial communities. | €13M | Series A first closeSeries A | Biotech | Germany | Investors | |
| CN Coherence NeuroCompany profile Investigational implants and bioelectronic systems for monitoring and treating cancer. Investigational implants and bioelectronic systems for monitoring and treating cancer. | £1.9M | December 2022 pre-seed announced March 2023Pre-seed | Biotech, Healthtech | United States | Investors | |
| AT Alchemab TherapeuticsCompany profile Alchemab Therapeutics develops antibody medicines by studying people resilient to disease. Alchemab Therapeutics develops antibody medicines by studying people resilient to disease. | £1.7M | Biomedical Catalyst grantUndisclosed | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.